Latest "Galectin Therapeutics" News Stories

10:38 EDT 29th August 2015 | BioPortfolio

Here are the most relevant search results for "Galectin Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Galectin Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Galectin Therapeutics for you to read. Along with our medical data and news we also list Galectin Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Galectin Therapeutics Companies for you to search.

Showing "Galectin Therapeutics" News Articles 1–25 of 54

Relevant

Association of Serum Galectin-3 Levels and Atrial Remodeling

Learn more about how galectin-3 level is associated with markers of atrial remodeling. Journal of Cardiovascular Electrophysiology

Galectin Therapeutics: Where There Is Smoke There Is Fire

First Automated Test for Galectin-3 Now Available in U.S.

WALTHAM, Mass., July 6, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today announced that the ARCHITECT® Galectin-3 assay is now available. This automated blood test was cleared by the United States Food and Drug Administration (FDA) for use in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed ...

Galectin Therapeutics to Present at LD Micro Invitational Conference

NORCROSS, Ga., May 28, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that James Czirr, executive chairman, will present a corporate overview and update at the LD Micro Invitational Conference on June 2, 2015, at 4:00 p.m. Pacific time. The conference is being held at t...

Galectin Therapeutics to Present at the 27th Annual ROTH Conference

NORCROSS, Ga., March 2, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that Harold, Shlevin, Ph.D, chief operating officer, will present a corporate overview and update at the 27th Annual ROTH Conference on March 9, 2015 at 11:00 a.m. Pacific time. The conference is bei...

BG Medicine Submits 510(k) to FDA for Additional Indication for the BGM Galectin-3(R) Test

WALTHAM, Mass., March 31, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today reported that it has filed a 510(k) Premarket Notification with U.S. Food and Drug Administration (FDA) for regulatory clearance of an additional indication for the BGM Galectin-3 Test. The filing incorporates data generated from a study in which levels of the pr...

Galectin Therapeutics Reports 2014 Financial Results, Provides Business Update

NORCROSS, Ga., March 18, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the year ended December 31, 2014. These results are included in the Company's Annual Report on Form 10-K, which has been filed with the U.S. Securities and Exchange Commiss...

Galectin Therapeutics to Webcast Corporate Update Following Annual Meeting of Stockholders

NORCROSS, Ga., May 15, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT) will webcast a corporate update at 9:45 A.M. ET on Thursday, May 21, 2015, immediately following the business portion of the Company's Annual Meeting of Stockholders. Additionally, Peter Traber, M.D., president, chief executive officer and chief medical officer will discuss the Company's pipeline of galectin inhib...

Galectin Therapeutics Names Dr. Marc Rubin Lead Independent Director

NORCROSS, Ga., June 3, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reports that Marc Rubin, M.D. has been elected by the independent members of the board of directors as the lead independent director. Dr. Rubin has been a member of the Galectin board of directors since 2011 and...

Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation

Galectin-8 promotes regulatory T-cell differentiation by modulating IL-2 and TGFβ signaling

Melanoma Cell Galectin-1 Ligands Functionally Correlate with Malignant Potential

Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis

NORCROSS, Ga., June 29, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the screening of the first five patients in its Phase 2 clinical trial with GR-MD-02 in nonalcoholic steatohepatitis (NASH) with cirrhosis. This study, the NASH-CX trial, is a multicenter, randomi...

Galectin Therapeutics Presented Research With GR-MD-02 at the American Association for the Study of Liver Diseases Industry Colloquium

NORCROSS, Ga., March 24, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that Peter G. Traber, M.D., president, chief executive officer and chief medical officer, delivered an invited presentation of the Company's research with lead compound GR-MD-02 in non-alcoholic steatohep...

Galectin Therapeutics Inc. Appoints Adam E. Allgood, Pharm.D., R.Ph., as Executive Director of Clinical Development

NORCROSS, Ga., July 15, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the appointment of Adam E. Allgood, Pharm.D., R.Ph. as executive director of clinical development, effective immediately. Dr. Allgood is an experienced industry professional with more than 28 ye...

Galectin Therapeutics Engages PPD to Conduct GR-MD-02 Phase 2 Trial in NASH, Submits Special Protocol Assessment to FDA

NORCROSS, Ga., March 12, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces it has engaged the contract research organization Pharmaceutical Product Development, LLC (PPD) to conduct the Phase 2 trial with GR-MD-02 for the treatment of liver fibrosis and resultant portal hyperten...

Galectin Therapeutics Provides Phase 2 NASH Program Update and Reports Second Quarter 2015 Financial Results

NORCROSS, Ga., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the three and six months ended June 30, 2015. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Ex...

Kruppel-like factor 4 (KLF4; EZF); galectin-3 (LGALS3)

Cell culture and mouse studies suggest inhibiting

Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases

NORCROSS, Ga., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for patent application number 13/726,900, titled "Galactose-pronged polysaccharides in a formulation for antifibrotic therapi...

Galectin Therapeutics Reports First Quarter 2015 Financial Results, Provides Business Update Including Phase 2 NASH Program

NORCROSS, Ga., May 11, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the three months ended March 31, 2015. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange C...

Targeted inhibition of galectin 1 by thiodigalactoside dramatically reduces body weight gain in diet-induced obese rats

Galectin-1 Protein Therapy Prevents Pathology and Improves Muscle Function in the mdx Mouse Model of Duchenne Muscular Dystrophy

BG Medicine Welcomes U.S. Market Introduction of Automated Galectin-3 Test at the 2015 American Association for Clinical Chemistry Annual Meeting

WALTHAM, Mass., July 27, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today that, in conjunction with the U.S. market introduction of automated testing for galectin-3, clinical and analytical performance data for galectin-3 testing using an Abbott ARCHITECT® automated immunoassay analyzer will be presented at the 2015 American Association for Clinical Chemistry (AACC) Annua...

Exalenz jumps after FDA cirrhosis trial approval

The Israeli firm has received a boost following the announcement of a joint trial with Galectin Therapeutics.

Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam

NORCROSS, Ga., May 14, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reports that in an open-label Phase 1 study with 8 mg/kg dose of GR-MD-02 and 2 mg/kg dose of midazolam there was no drug-drug interaction and no serious adverse events or drug-related adverse events were observ...



Advertisement
 
Advertisement
 

News Quicklinks